Why NPS Pharmaceuticals Is Up After Earnings
Shares of orphan drugmaker NPS Pharmaceuticals are up more than 4% in intraday trading. The company, which gained Food and Drug Adminstration approval for its short bowel syndrome drug Gattex back in December, reported its first-quarter earnings and revealed the prescription numbers and sales of its drug launch. In the following video, health care analyst Max Macaluso discusses these details and three key takeaways from the company's first quarter.
While looking at past performance is useful, the best investing approach is to choose great companies and stick with them for the long term. The Motley Fool's free report "3 Stocks That Will Help You Retire Rich" names stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.
The article Why NPS Pharmaceuticals Is Up After Earnings originally appeared on Fool.com.
Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.